Pharmacology and neuroprotective properties of rasagiline
by
Finberg JP, Lamensdorf I,
Commissiong JW, Youdim MB.
Pharmacology Unit,
Rappaport Faculty of Medicine,
Technion, Haifa, Israel.
J Neural Transm Suppl. 1996;48:95-101

ABSTRACT

Rasagiline [R(+)-N-propargyl-1-aminoindane] is a selective irreversible inhibitor of MAO-B which is not metabolised to amphetamine-like derivatives. Like deprenyl, when given to rats in a dose selective for inhibition of MAO-B, it does not affect striatal extracellular fluid dopamine levels, but when administered chronically (21 days) it increased striatal microdialysate dopamine without reduction in deaminated metabolites. Similarly to deprenyl, rasagiline (10(-6)M) increased the percentage of tyrosine hydroxylase positive cells in a primary culture of rat fetal mesencephalic cells (6 days in culture). Rasagiline, but not deprenyl, also increased the number of neurons per field in this organotypic culture.


MAOIs
Rasagiline
Neuroprotection
Rasagiline: structure
MAO-b inhibitors/PD
Anti-apoptotic activity
Molecular mechanisms
Rasagiline pharmacology
Antioxidant strategies against aging
Anti-Alzheimer/anti-Parkinson's drugs
Rasagiline versus selegiline metabolites
Rasagiline v selegiline: neuronal survival effects
Rasagiline (Agilect) in early Parkinson's disease


Go To Good Drug Guide
Refs
HOME
HedWeb
Selegiline.com
BLTC Research
Nootropics.com
The Good Drug Guide
Paradise-Engineering
Supercentenarians.com
The Hedonistic Imperative
MDMA: Utopian Pharmacology